129 related articles for article (PubMed ID: 17661715)
1. TRAIL-receptor antibodies as a potential cancer treatment.
Buchsbaum DJ; Forero-Torres A; LoBuglio AF
Future Oncol; 2007 Aug; 3(4):405-9. PubMed ID: 17661715
[TBL] [Abstract][Full Text] [Related]
2. TRAIL death receptors and cancer therapeutics.
Huang Y; Sheikh MS
Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
[TBL] [Abstract][Full Text] [Related]
4. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
Cretney E; Takeda K; Smyth MJ
Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
[TBL] [Abstract][Full Text] [Related]
5. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
6. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
Ashkenazi A; Holland P; Eckhardt SG
J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
Marini P; Denzinger S; Schiller D; Kauder S; Welz S; Humphreys R; Daniel PT; Jendrossek V; Budach W; Belka C
Oncogene; 2006 Aug; 25(37):5145-54. PubMed ID: 16636678
[TBL] [Abstract][Full Text] [Related]
8. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
9. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
Wang S
Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
[TBL] [Abstract][Full Text] [Related]
10. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
11. Targeting TRAIL death receptors.
Oldenhuis CN; Stegehuis JH; Walenkamp AM; de Jong S; de Vries EG
Curr Opin Pharmacol; 2008 Aug; 8(4):433-9. PubMed ID: 18625341
[TBL] [Abstract][Full Text] [Related]
12. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers.
Kendrick JE; Estes JM; Straughn JM; Alvarez RD; Buchsbaum DJ
Gynecol Oncol; 2007 Sep; 106(3):614-21. PubMed ID: 17602728
[TBL] [Abstract][Full Text] [Related]
14. Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2.
Marini P
Curr Opin Mol Ther; 2006 Dec; 8(6):539-46. PubMed ID: 17243490
[TBL] [Abstract][Full Text] [Related]
15. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
[TBL] [Abstract][Full Text] [Related]
16. Targeting TRAIL agonistic receptors for cancer therapy.
Carlo-Stella C; Lavazza C; Locatelli A; Viganò L; Gianni AM; Gianni L
Clin Cancer Res; 2007 Apr; 13(8):2313-7. PubMed ID: 17438088
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of TRAIL and its death receptors in cervical cancer.
Maduro JH; Noordhuis MG; ten Hoor KA; Pras E; Arts HJ; Eijsink JJ; Hollema H; Mom CH; de Jong S; de Vries EG; de Bock GH; van der Zee AG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):203-11. PubMed ID: 19695437
[TBL] [Abstract][Full Text] [Related]
18. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
Zhang X; Li W; Olumi AF
Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
[TBL] [Abstract][Full Text] [Related]
19. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
20. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
Tolcher AW; Mita M; Meropol NJ; von Mehren M; Patnaik A; Padavic K; Hill M; Mays T; McCoy T; Fox NL; Halpern W; Corey A; Cohen RB
J Clin Oncol; 2007 Apr; 25(11):1390-5. PubMed ID: 17416859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
